Recent Serologic Studies with Potential Impact on WNV Blood Screening Wayne Hogrefe, Harry Prince Focus Technologies.

Slides:

Advertisements

Similar presentations

Instructions for users This slide presentation provides an overview of the diagnostic and laboratory testing aspects of JE. Below many of the slides, there.

Advertisements

To evaluate sensitivity, each of the 76 specimens (38 serum pairs) were tested using three serology tests. All testing was performed at the university.

Laboratory Diagnosis of HSV Infection Peter Leone, MD Associate Professor of Medicine University of North Carolina.

Mosquito-borne Arbovirus Surveillance in West Virginia Rachel Radcliffe, DVM, MPH CDC Career Epidemiology Field Officer Division of Infectious Disease.

Blood Products Advisory Committee Meeting Harold S. Gaithersburg, MD December 14, 2010 Harold S. Margolis, MD Chief, Dengue Branch Centers for Disease.

An Introduction to HIV Incidence Surveillance (HIS) in California California Department of Public Health Office of AIDS.

West Nile Virus: Surveillance and Clinical Issues Anne Kjemtrup, DVM, MPVM, Ph.D. California Department of Public Health Vector-Borne Disease Section 1.

Use of avidity reagent. Panbio Buffered Avidity Reagent Mild protein-denaturing solution that may be useful in differentiating recent infections from.

Primary HIV Infection: the CDC study Pragna Patel, MD MPH Medical Epidemiologist Behavioral and Clinical Surveillance Branch DHAP, CDC February 28, 2005.

WNV Human Case Investigation and Reporting Kimberly Signs, DVM Michigan Department of Community Health.

Algorithms and Testing Results for West Nile/Arbovirus Testing (2002) used at Michigan Department of Community Health H. Kapoor, P. Clark, F. P. Downes,

Update on West Nile virus and Blood Safety November 3, 2005 Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.

DIAGNOSIS OF WEST NILE VIRUS INFECTION IN ANIMALS Jon S. Patterson, DVM, PhD, DACVP Roger K. Maes, DVM, PhD Diagnostic Center for Population and Animal.

Testing algorithms used at Bureau of Labs Michigan Department of Community Health Information on testing algorithms for processing and reporting serological.

Enhancing HIV/AIDS Surveillance in California California Department of Public Health Office of AIDS Guide for Health Care Providers.

DEPARTMENT OF HEALTH RESEARCH INSTITUTE FOR TROPICAL MEDICINE Ebola Virus Disease Diagnosis Catalino S. Demetria, DVM.

Dengue Virus and Its Risk to the U.S. Blood Supply

R Diagnostics June 19, 2003 WNV FDA BPAC MeetingPCR NAT Blood Screening TaqScreen West Nile Virus Program - Roche Update James L. Gallarda, Ph.D. Roche.

Laboratory Investigation

TMA Assay for Detection of West Nile Virus BPAC Meeting - March 13, 2003 Cristina Giachetti, Ph.D. J.Linnen; A.Broulik; W. Wu; J.Cline; M.Lewis; G.Dennis;

21 August 2015 Samreen Ijaz Virus Reference Department Health Protection Agency Indigenous HEV infection in the UK: a hazard for blood donation?

Reentry for Donors Deferred Based on Anti-HBc Test Results November 3, 2005 BPAC Meeting FDA/CBER/OBRR/DETTD.

Transmissibility of B19 by transfusion: evaluation of donor viremia prior to performing a linked donor-recipient study M Busch, representing REDS-II Parvo.

West Nile virus: the disease and Panbio product training.

REAL-TIME SCREENING FOR WEST NILE VIRUS (WNV) OF ORGAN DONORS Claudia Chinchilla, CLSpMB 1, Jaime Siriban, CLS 1, Dem Brucal, CLS 1, James Schellenberg,

Hema Kapoor MD. SM (NRM) Virology Section manager Bureau of laboratories Michigan Department of community Health Lansing Michigan Laboratory Issues and.

Maria Rios, Ph.D. CBER/FDA Blood Products Advisory Committee May 1st, WNV Epidemiology & FDA’s Recommendations on the Use of NAT to Reduce the.

Laboratory Issues and West Nile Virus Hema Kapoor MD. SM (NRM)

DIAGNOSIS OF HIV INFECTION THE LABORATORY BY DR. K.BUJJIBABU.MD.

Background Recruitment strategies for organ and tissue donors are different, and although some organ donors do eventually become tissue donors, organ donors.

E A 1 Parvovirus B19 and HAV Screening of Whole Blood Donations SL Stramer, KL Kane, ML Beyers, RY Dodd, American Red Cross and RIF Smith, National.

West Nile Virus Surveillance Ingrid Garrison, DVM, MPH, DACVPM State Public Health Veterinarian September 16, 2015.

Detection of Dengue Virus RNA in Blood Donors from Honduras and Brazil with a Prototype Transcription-Mediated Amplification Assay.

Theresa L. Smith, MD, MPH Division of Vector-Borne Infectious Diseases Centers for Disease Control and Prevention Fort Collins, CO West Nile Virus Epidemiology.

Retrospective and Prospective U.S. Donor MRV Surveillance and Transmission Studies Michael Busch, MD, PhD Blood Systems Research Institute Dept of Laboratory.

Persistent human erythrovirus infection in blood donors National Blood Service, UK Div. Transfusion Medicine, University of Cambridge, UK Public Health.

Update on Assay Development George J. Dawson, Ph.D. Infectious Diseases: Core R & D Abbott Laboratories West Nile Virus.

Approval Criteria for Assays for Testing Blood Donors for West Nile Virus Robin Biswas, M.D. CBER, FDA Blood Products Advisory Committee Meeting March.

Panbio Dengue ELISAs.

Overview of Data on Blood Donor Testing and Plan for Studies to Characterize Rates and Consequences of Transfusion Transmission of Dengue Virus Michael.

1 Blood Systems Trypanosoma cruzi and Chagas Disease Studies and Potential Strategies for Targeted Testing of Donors Blood Products Advisory Committee.

1 Procleix ® WNV Assay: A TMA-based Assay for Screening Blood Donations for West Nile Virus RNA Jeff Linnen, Ph.D. Research and Development Gen-Probe Incorporated,

Current Status of Issues Related to West Nile virus testing and donor screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.

Progress in West Nile virus Testing and Donor Screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.

Other Animal Species Large and growing list of animals that have tested positive for WNV Current list at U.S. Geological Survey’s National Wildlife Health.

West Nile Virus: Pathogenesis and Diagnostic Tools Maria Rios, PhD - Senior Staff Fellow Laboratory of Molecular Virology DETTD/OBRR/CBER/FDA WNV epidemic.

Development of Standard Reagents for WNV NAT M. Rios, A. Grinev, K. Sirnivasan, O. Wood, S. Daniel, I. Hewlett CBER/FDA.

Anti-B19 screening for safe cellular blood products for at–risk patients SoGAT XVIII, USA, May 24-25th, 2005 Harry Bos on behalf of Project Group Parvo.

Surveillance & Environmental Health West Nile Virus Seroprevalence: Results of Enhanced Surveillance Program.

Avidity determination of IgG in diagnosis of tick-born encephalitis Hana Zelená Jiří Januška Jan Raszka Virology department, National Reference Laboratory.

Management of Donors and Units that Test HBV NAT Positive: Current Considerations July 21, 2005 BPAC Meeting Robin Biswas, M.D. FDA/CBER/OBRR/DETTD.

SoGAT 2005 Donor screening for parvovirus B19 antibodies: Reducing or eliminating the risk of transmission SoGAT 2005 Gordon Elliott Biotrin 93 The Rise.

Panbio Dengue Duo Cassette

PROPOSED CANDIDATE MATERIAL FOR A WHO PANEL FOR SEROLOGICAL REFERENCE RESULTS OF THE FEASIBILITY STUDIES WITH SERA FROM TC I REGION RESULTS OF THE FEASIBILITY.

Ro / BSD Hessen Institut für Transfusionsmedizin SoGAT XVII, Paris, Paris 2004 B19 Overview of Testing for Blood Banks W. Kurt Roth Red Cross Blood Transfusion.

 Mosquito  Horses  The warm months  dawn and dusk.  Hot, dry weather Reference: "West Nile Virus Information."

Validation of Nucleic Acid and Serological Tests to Screen Blood and Plasma donors for Acute infection with West Nile virus Hira Nakhasi, Ph.D. Director,

Update on West Nile Virus – United States, Eileen C. Farnon, MD Arboviral Diseases Branch Division of Vector-Borne Infectious Diseases Centers.

Risk assessment: The Safety of Blood Products presented by Dr. Thomas R. Kreil Baxter BioScience on behalf of the PPTA Pathogen Safety Steering Committee.

Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection - Update - Alan E. Williams, Ph.D. Director,

CBER Update on status of West Nile virus test, lot release and validation panel development Indira Hewlett, Ph.D CBER/FDA Blood Products Advisory Committee.

Dengue fever caused by dengue virus (DENV), a member of Flaviviridae leads to large global disease burden. Detection of immunoglobulin M (IgM) and nucleic.

RESULTS Division of Arboviruses, Center for Immunology and Pathology, National Institute of Health, Korea Centers for disease control, Osong, Korea BACKGROUND.

A set of whole numbers and opposites ADDING POSITIVE AND NEGATIVE INTEGERS.

CBER Current Considerations for Blood Donor Screening for West Nile Virus Pradip N. Akolkar, Ph.D. Maria Rios, Ph.D. DETTD, OBRR Blood Products Advisory.

Abbott Laboratories ConfidentialPage 1 Update on West Nile Virus George J. Dawson, Ph.D. Abbott Laboratories.

Diagnostic Testing for Zika Virus Frederick S. Nolte, PhD, D(ABMM), F(AAM) Professor and Vice-Chair for Laboratory Medicine Department of Pathology and.

Specimen Collection Guide for Cattle or Horses with Suspected Rabies, West Nile Virus Encephalitis or Bovine Spongiform Encephalopathy (BSE) Adapted from.

ImmunoWELL Zika Virus Serology.

Schematic representation of the reactivities of IgM antibodies induced against Gly-Ala repeats of EBNA-1 and against glycine-rich motifs of HCMV antigens,

Presentation transcript:

Recent Serologic Studies with Potential Impact on WNV Blood Screening Wayne Hogrefe, Harry Prince Focus Technologies

Focus WNV IgG and IgM ELISA Focus-based WNV serology technology currently used in: Reference laboratories Public health laboratories GenProbe IND study Research projects for donor screening

Recent Studies using Focus IgG and IgM ELISA Utility of the Focus Technologies WNV IgM Capture ELISA Testing CSF; Lape-Nixon, et al., AMLI 2003 Prince and Hogrefe, CDLI 10 :764, 2003 Prevalence of West Nile Virus Infection in Frozen Donor Plasma Components Recalled from the Peak Epidemic period in 2002; Tobler, LH, et al., ASH 2003

CSF IgM Testing - Key Finding 1188 Serum/CSF pairs tested in 2002  Negative/Negative (85.4%)  Positive/Negative - 43 (3.6%)  Positive/Positive (10.9%)  Negative/Positive - 0

IgM Persistence Roehrig, et al. EID 9 :376, 2003  7 of 12 (58%) WNV-infected encephalitis patients had detectable IgM at 500 days Prince and Hogrefe, CDLI 10 :764, 2003  Not clinically defined patients, rather sequentially submitted samples for WNV serology in 2002  5/13 (46%) with detectable IgM at days after first submitted sample

Prevalence of West Nile Virus Infection in Frozen Donor Plasma Components Recalled from the Peak Epidemic Period in 2002 Collaborative study between ABC centers and the REDS Study, sponsored by NHLBI December 2002 frozen products collected during the epidemic period from areas of high WNV activity were collected and quarantined 1468 frozen plasma components collected between June 23, 2002 and September 28, 2002 Sample source: IL - 53%; LA - 17%; MI - 17%; MS,OH, KY, TX, NE - 13%

WNV Antibody Profile IgGIgMFocus ELISA # (%) NonreactiveNonreactive1429 (97%) ReactiveReactive7 (0.48%) NonreactiveReactive1 (0.07%) ReactiveNonreactive23 (1.57%) EquivocalNonreactive8 (0.54%) Total1468

IgG Reactive Samples Twenty-three IgG positive/IgM negative samples  13 (57%) with Index values of  7 (30%) with Index values of  3 (13%) with Index values of >3.0 Seven IgG positive/IgM positive samples  2 (29%) with Index values of 1.5  1 (14%) with Index values of  4 (57%) with Index values of >3.0

PRNT and IgM Reactive Samples IgM ELISAIgG ELISA WNV PRNT SLE PRNT 1.14 <1.30<10<

GenProbe TMA and Serology One of 1468 samples - TMA positive  Focus IgM and IgG negative, PRNT negative The 7 Focus IgM positive samples repeat 10-fold replicate TMA testing  one sample 7/10 replicates reactive  one sample 2/10 replicates reactive